Equillium Raises Capital Through Private Equity Securities Sale

Equillium ( (EQ) ) just unveiled an announcement.

On March 11, 2026, Equillium, Inc. entered into a securities purchase agreement with RA Capital Healthcare Fund, L.P. for a private placement of 1,179,508 common shares and a pre-funded warrant for up to 17,698,593 additional shares, priced off the five-day Nasdaq average, to raise approximately $35 million in gross proceeds. The pre-funded warrant, which carries a de minimis exercise price, is exercisable on a cashless basis subject to a 19.99% ownership cap, and is accompanied by a registration rights agreement requiring Equillium to register the resale of the securities with the U.S. Securities and Exchange Commission or face cash penalties.

The company expects to use the net proceeds from the anticipated March 13, 2026 closing, together with existing cash, to advance development of its EQ504 candidate and for working capital and general corporate purposes. By tapping a specialized healthcare investor via an exempt private placement under Section 4(a)(2) of the Securities Act, Equillium strengthens its near-term funding runway without immediate public market dilution, while committing to future tradability of the new securities through SEC registration, a structure that balances investor liquidity needs with regulatory and ownership constraints.

The most recent analyst rating on (EQ) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Equillium stock, see the EQ Stock Forecast page.

Spark’s Take on EQ Stock

According to Spark, TipRanks’ AI Analyst, EQ is a Neutral.

The score is held back primarily by weak financial performance (sharp TTM revenue decline, widening losses, and persistent negative operating/free cash flow), partially offset by a low-debt balance sheet. Technicals are comparatively strong with the price above major moving averages and positive MACD, but valuation remains constrained by unprofitability and no dividend yield support.

To see Spark’s full report on EQ stock, click here.

More about Equillium

Equillium, Inc. is a U.S.-based biopharmaceutical company focused on developing innovative therapeutics, including its EQ504 program. The company operates in the healthcare sector, targeting unmet medical needs and funding its clinical and preclinical pipeline through equity and warrant financings in the capital markets.

Average Trading Volume: 627,139

Technical Sentiment Signal: Buy

Current Market Cap: $126M

For a thorough assessment of EQ stock, go to TipRanks’ Stock Analysis page.